Literature DB >> 27428315

The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis.

Pasquale Ambrosino1, Roberta Lupoli1, Alessandro Di Minno2, Luciano Tarantino3, Gaia Spadarella1, Paolo Tarantino1, Aurelio Nasto4, Aldo Celentano1, Matteo Nicola Dario Di Minno5.   

Abstract

BACKGROUND/
OBJECTIVES: Some studies suggest that patients with hepatitis C virus (HCV) infection have an increased risk of coronary artery disease (CAD) and cerebrovascular disease. Unfortunately, available data on this association are widely variable. We have performed a systematic review and meta-analysis of literature to evaluate the risk of cardio-cerebrovascular disease (CCD) associated with HCV.
METHODS: Studies reporting on CCD risk associated with HCV were systematically searched in the PubMed, Web of Science, Scopus and EMBASE databases.
RESULTS: Twenty-seven studies (34 data-sets) showed a significantly increased CCD risk in 297,613 HCV patients as compared with 557,814 uninfected controls (OR: 1.428; 95% CI: 1.214, 1.681). These results were confirmed when separately considering the risk of CAD (20 studies, OR: 1.382; 95% CI: 1.103, 1.732) and of cerebrovascular disease (13 studies, OR: 1.485; 95% CI: 1.079, 2.044). Similar results were confirmed when analyzing 21 studies reporting adjusted risk estimates (OR: 1.448; 95% CI: 1.218, 1.722) and when, after excluding studies defining CAD as positive angiographic or electrocardiographic evidence, we specifically included the 17 studies reporting on acute CCD-related events (OR: 1.357; 95% CI: 1.103, 1.670). Moreover, 4 studies evaluating CCD-related deaths showed a higher risk in HCV patients than controls (OR: 1.772; 95% CI: 1.448, 2.168; P<0.0001). Meta-regression models suggested a direct association between prevalence of cirrhosis and difference in CCD risk between HCV patients and controls.
CONCLUSIONS: Results of our large meta-analysis suggest that HCV-infected subjects experience an increased risk of CCD. This should be considered to plan specific cardiovascular prevention strategies in this clinical setting.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Hepatitis C; Myocardial infarction; Stroke

Mesh:

Year:  2016        PMID: 27428315     DOI: 10.1016/j.ijcard.2016.06.337

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  21 in total

1.  Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.

Authors:  Matteo Nicola Dario Di Minno; Pasquale Ambrosino; Antonio Riccardo Buonomo; Biagio Pinchera; Ilenia Calcaterra; Manuel Crispo; Riccardo Scotto; Francesco Borgia; Consalvo Mattia; Ivan Gentile
Journal:  Intern Emerg Med       Date:  2019-08-08       Impact factor: 3.397

Review 2.  CON: Noninvasive Imaging Is the Preferred Strategy for Cardiovascular Risk Stratification in This Patient.

Authors:  Shravan Dave; Abbey Barnard; Michel Mendler
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

3.  Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons.

Authors:  K W Chew; D Bhattacharya; T B Horwich; P Yan; K A McGinnis; C Tseng; M S Freiberg; J S Currier; A A Butt
Journal:  J Viral Hepat       Date:  2017-04-10       Impact factor: 3.728

Review 4.  Cardiovascular Implications of Immune Disorders in Women.

Authors:  Caitlin A Moran; Lauren F Collins; Nour Beydoun; Puja K Mehta; Yetunde Fatade; Ijeoma Isiadinso; Tené T Lewis; Brittany Weber; Jill Goldstein; Igho Ofotokun; Arshed Quyyumi; May Y Choi; Kehmia Titanji; Cecile D Lahiri
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

5.  Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United States.

Authors:  Jessica Williams-Nguyen; Stephen E Hawes; Robin M Nance; Sara Lindström; Susan R Heckbert; H Nina Kim; W Chris Mathews; Edward R Cachay; Matt Budoff; Christopher B Hurt; Peter W Hunt; Elvin Geng; Richard D Moore; Michael J Mugavero; Inga Peter; Mari M Kitahata; Michael S Saag; Heidi M Crane; Joseph A Delaney
Journal:  Am J Epidemiol       Date:  2020-06-01       Impact factor: 4.897

6.  HIV, hepatitis C virus and risk of new-onset left ventricular dysfunction in women.

Authors:  Sanyog G Shitole; Jason M Lazar; David B Hanna; Ryung S Kim; Kathryn Anastos; Mario J Garcia; Phyllis C Tien; João A C Lima; Robert C Kaplan; Jorge R Kizer
Journal:  AIDS       Date:  2021-08-01       Impact factor: 4.632

7.  Hepatitis B virus infection and decreased risk of stroke: a meta-analysis.

Authors:  Yaqin Wang; Jianping Xiong; Xi Chen; Meng Niu; Xiaowei Chen; Yuheng Guan; Kechuang Zheng; Ke Xu
Journal:  Oncotarget       Date:  2017-07-26

Review 8.  Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review.

Authors:  Ahmed Babiker; Jean Jeudy; Seth Kligerman; Miriam Khambaty; Anoop Shah; Shashwatee Bagchi
Journal:  J Clin Transl Hepatol       Date:  2017-08-31

Review 9.  Nontraditional Cardiovascular Biomarkers and Risk Factors: Rationale and Future Perspectives.

Authors:  Irene Traghella; Francesca Mastorci; Alessia Pepe; Alessandro Pingitore; Cristina Vassalle
Journal:  Biomolecules       Date:  2018-06-15

10.  Coexistent Ipsilateral Internal Carotid Artery Occlusion and Cerebral Venous Thrombosis in Hepatitis C.

Authors:  Karan Seegobin; Somphanh Khousakhoun; Ryan Crooks; Satish Maharaj; Cherisse Baldeo
Journal:  J Investig Med High Impact Case Rep       Date:  2018-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.